How Does Salivary Protein Binding Modify Chlorhexidine Release from Veterinary Oral Tablets?

Chlorhexidine (Hibitane) veterinary grade API is processed into 150 mg and 300 mg non-chewable oral tablets for canine and feline gingivostomatitis through wet granulation rather than direct compression. A non-aqueous granulating fluid consisting of 5.0% w/w povidone K-30 in isopropyl alcohol is applied to a chlorhexidine dihydrochloride and dicalcium phosphate dihydrate blend in a top-spray fluid-bed granulator at inlet air temperature 45°C to 55°C; the resulting granules are dried to residual moisture ≤1.5% w/w, milled through a 1.0 mm screen, and lubricated with 0.5% w/w magnesium stearate. Tablet compression is performed on a 12-station rotary press at 25 rpm to target hardness 70–100 N and friability below 1.0% per USP <1216>. Disintegration time is controlled at 15 min in 0.1 M HCl at 37°C per USP <701>. Direct compression is avoided because chlorhexidine gluconate solutions are hygroscopic and can cause punch filming during extended high-speed compression runs. The tablet matrix also excludes sodium lauryl sulfate and carboxymethylcellulose sodium; the cationic bisbiguanide interacts with these anionic polymers and surfactants to form electrostatic complexes that reduce free chlorhexidine below the 0.12% w/v threshold associated with oral hygiene activity. Dissolution testing in simulated canine saliva containing 0.3% w/v mucin at pH 7.4 shows a 10–15 min lag phase before linear release; this delay corresponds to salivary protein binding at the erosion front and is not observed in plain phosphate buffer. Tablets are intended for local oral retention rather than systemic absorption; published data on plasma concentrations after oral administration in dogs indicate negligible systemic exposure. Packaging is cold-form aluminum/aluminum blister because of humidity sensitivity; HDPE bottles with desiccant are acceptable if the closure is not opened for more than 30 days at 40°C/75% RH. The terminal veterinary oral hygiene tablet is a non-chewable product used twice daily under veterinary direction.

Teat dip concentrate formulation begins with a 5.0% w/v chlorhexidine gluconate stock solution adjusted to pH 5.5–7.0 with glucono-delta-lactone; this pH window keeps the chlorhexidine base below its pKa of 10.8 in the ionized bactericidal form while avoiding free-base precipitation. The concentrate contains 10% w/v sorbitol and 2% w/v glycerin as humectants, and the working post-milking solution is prepared by 1:10 dilution to a final chlorhexidine gluconate concentration of 0.5% w/v. Pre-milking dips are diluted to 0.25%–0.35% w/v; the higher concentration is reserved for post-milking barrier films because residual milk protein and soil load reduce free chlorhexidine activity by 0.5–1.2 log10 in EN 1656:2019 suspension tests under 0.3% bovine serum albumin conditions. In-line mixing uses a high-shear rotor-stator mixer at 3000 rpm for 15 min, followed by 24 h quiescent storage at 20–25°C to allow hydrated silica thickener to reach final viscosity of 150–300 mPa·s. Storage vessels are made from 316L stainless steel or high-density polyethylene; carbon steel is not suitable because chloride ions in chlorhexidine gluconate concentrates promote pitting corrosion at pH below 6.0. The final teat dip must achieve at least 5.0 log10 reduction of Staphylococcus aureus and Streptococcus uberis under EN 1656:2019 clean conditions and at least 3.0 log10 under dirty conditions; yeasticidal activity is assessed by EN 16437:2014 against Candida albicans. Post-milking barrier dips include 4% w/w polyvinylpyrrolidone as a film former; this addition increases contact time on teat skin but may delay evaporation and require a drying interval of 5–10 min before cows exit the parlor. Emollient loading above 10% w/w reduces contact kill rate; production-scale batches therefore require revalidation at the lower emollient boundary of 8% w/w and upper boundary of 12% w/w. The terminal product is a post-milking barrier teat dip or pre-milking udder hygiene solution for dairy cattle.

Pre-injection Antisepsis and Wound Lavage Solutions in Polypropylene Ampoules

Chlorhexidine veterinary grade API is dissolved to 0.05%–0.1% w/v in sterile water for irrigation with pH 5.0–6.5 using the gluconate salt; this concentration range provides 30-second pre-injection skin preparation without tissue staining. The term injection in veterinary practice refers to the antiseptic preparation of injection sites rather than a parenteral finished dosage form; chlorhexidine should not be formulated into an injectable product because intravenous exposure is associated with pulmonary edema, hemolysis, and acute respiratory distress in published case reports. A 2.0% w/v chlorhexidine gluconate and 70.0% v/v isopropanol solution is filled into single-use polypropylene or polyethylene ampoules under ISO 14644-1 Class 8 conditions after terminal filtration through 0.22 µm polyethersulfone membrane. Contact time of 30–60 s is required before skin puncture; the solution is allowed to air-dry rather than wiped off, as the drying interval contributes to reduction of resident bacterial flora. The antiseptic solution is not suitable for use in body cavities, on the central nervous system, or in the middle ear when the tympanic membrane is perforated because chlorhexidine is ototoxic in these tissues. Wound lavage solutions at 0.05% w/v are used in dogs and cats for irrigation of contaminated traumatic wounds; the solution is delivered by a 35-mL syringe and a 19-gauge blunt cannula at low pressure to avoid forcing bacteria into soft tissue planes. The packaged solution must meet USP <51> antimicrobial effectiveness testing and be stored at 15–30°C; freeze-thaw cycles below 0°C cause chlorhexidine gluconate to separate from the aqueous phase, and reheating above 40°C can generate chloroaniline-related degradation products. Incompatibilities include anionic surfactants, hypochlorite, agar, and carboxymethylcellulose; normal saline should not be used as a diluent above 0.1% w/v because salt-induced precipitation may reduce available free chlorhexidine. The terminal product is a single-use antiseptic solution for injection-site preparation and a low-concentration wound lavage solution.

When Dusting Powders and Granules Are Preferred Over Aqueous Vehicles for Exudative Dermatoses

In veterinary dermatology, exudative dermatoses in cattle, sheep, and companion animals are managed with 1.0% w/w chlorhexidine acetate dusting powder when aqueous vehicles prolong maceration. The active is dry-mixed with pregelatinized starch and zinc oxide in a V-blender at 25 rpm for 15 min; the blend is passed through a 100 µm stainless steel sieve and controlled by laser diffraction to a D90 ≤150 µm. Residual moisture after blending is held ≤1.0% w/w. Production areas above 60% RH cause chlorhexidine diacetate to agglomerate and shift the Carr index outside the 15–20 range; the milling room is therefore maintained at 20–25°C and 40% RH or below. Fumed silica at 0.5% w/w is added as a flow aid before packaging into high-barrier polyethylene terephthalate/aluminum foil/low-density polyethylene pouches. For granule dosage forms, a top-spray fluid-bed granulator is used with polyvinylpyrrolidone solution at atomizing air pressure of 1.0–1.5 bar and spray rate of 8–12 g/min; the dried granules are sized to 0.5–1.0 mm and filled into sachets or hard gelatin capsules. The terminal product is reconstituted with water to 0.5% w/v before topical application or applied as a dry powder to moist lesions once daily under veterinary direction. Published data on repeated 28-day dermal exposure in horses is limited; this route should be avoided in animals with known chlorhexidine hypersensitivity. The powder formulation must comply with USP <811> powder fineness and USP <51> antimicrobial effectiveness when reconstituted.

Medicated premixes for companion animal oral use are prepared by geometric dilution of chlorhexidine dihydrochloride into a maltodextrin-lactose carrier to a final concentration of 0.25%–1.0% w/w. The premix is mixed in a ribbon blender at 25 rpm for 15 min and passed through a 1.0 mm screen; blend uniformity is monitored by sampling 10 locations and must meet an acceptance value of ≤15.0 per USP <905>. Because chlorhexidine is poorly absorbed from the gastrointestinal tract, oral premix exposure is restricted to local activity in the oral cavity and upper digestive tract; published bioavailability data after oral administration in dogs is limited, but systemic absorption is considered minimal. The premix is included in feed at 50–100 mg/kg complete feed for plaque reduction in dogs and horses; authorization in food-producing species is not assumed and must be verified under the intended market's veterinary medicinal product regulations. Granulation of the premix is not performed unless the product is intended as a soluble oral granule; in that case the carrier is replaced with sucrose and the mixture is wet-granulated with 10% w/v polyvinylpyrrolidone solution in a high-shear granulator at impeller speed 250 rpm for 5 min. The resulting granules are dried at 45°C to residual moisture ≤1.0% w/w and filled into aluminum foil sachets. A terminal product should be labeled for oral cavity or dermatological use only and should not be administered parenterally.

Compounded Capsule and Tablet Intermediates for Exotic Species Require Preservative-Free Unit Operations

Compounded capsules for zoo and exotic animal protocols are filled on a semi-automatic capsule filling machine into size 3 or 4 hypromellose capsules at 5–20 mg per capsule. Neat chlorhexidine dihydrochloride API is not filled directly under ambient humidity; the encapsulation suite is maintained at 20–25°C and RH below 40% because adsorbed moisture causes capsule shell deformation and extends disintegration beyond 30 min within 30 days at 40°C/75% RH. A 1:10 dilution with microcrystalline cellulose is used to improve powder flow and reduce static adhesion to the capsule body. The capsule is not intended to be swallowed intact; it is opened and the content is dispersed in purified water at pH 5.5–6.5 immediately before use as an oral cavity rinse or topical wound flush. Tablet intermediates for exotic species are produced by dry blending and direct compression into 10 mg tablets using a single-punch press; the tablet matrix includes mannitol and crospovidone, but not stearic acid, because the carboxyl group can interact with the cationic biguanide. These tablets may be split or crushed for dose adjustment; friability is controlled at ≤1.0% per USP <1216> to ensure consistent splitting. Sterilization of these solid intermediates is not performed; terminal sterilization is not required for topical and oral cavity use, but microbial limits per USP <61> and USP <62> must be met. The final compounded product is assigned a beyond-use date not exceeding 30 days under refrigeration unless stability data support a longer interval.